CompletedPhase 1

A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD

United Kingdom7 participantsStarted 2024-09-20

Plain-language summary

This is the second in-human study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Serum creatinine level
✕. Total bilirubin, aspartate aminotransferase or alanine aminotransferase values
✕. Hematological or coagulation values outside the normal reference range

What they're measuring

The number of participants with Adverse Events (AEs), including treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs).

Timeframe: From Baseline Through Week 24

Trial details

NCT IDNCT06600425

SponsorReCode Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-06-06

View on ClinicalTrials.gov More Primary Ciliary Dyskinesia trials